| Identification | Back Directory | [Name]
URSODEOXYCHOLIC-2,2,4,4-D4 ACID | [CAS]
347841-46-7 | [Synonyms]
Ursodeoxycholic-d4 Acid
URSODEOXYCHOLIC-2,2,4,4-D4 ACID
Urosodeoxycholic Acid Impurity 28
Ursodeoxycholic acid-[d4] (Solution)
Ursodiol-d4 (Ursodeoxycholic Acid-d4)
Ursodeoxycholic Acid-2,2,4,4-d4 (Major)
Ursodeoxycholic Acid-d4 MaxSpec? Standard
URSODEOXYCHOLIC ACID (2,2,4,4-D4, 98%) 95% CHEMICAL PURITY
URSODEOXYCHOLIC ACID (2,2,4,4-D4, 98%) 100 UG/ML IN METHANOL
(4R)-4-[(3R,5S,7S,8R,10S,13R,17R)-2,2,4,4-tetradeuterio-3,7-dihydroxy-10,13-dimethyl-3,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
(4R)-4-[(3R,5R,7S,8R,9S,10S,13R,17R)-2,2,4,4-tetradeuterio-3,7-dihydroxy-10,13-dimethyl-3,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
(4R)-4-[(3R,5R,7S,8R,9S,10S,13R,14S,17R)-2,2,4,4-tetradeuterio-3,7-dihydroxy-10,13-dimethyl-3,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | [Molecular Formula]
C24H40O4 | [MDL Number]
MFCD01317390 | [MOL File]
347841-46-7.mol | [Molecular Weight]
392.58 |
| Chemical Properties | Back Directory | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly), | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic | [CAS Number Unlabeled]
128-13-2 |
| Safety Data | Back Directory | [WGK Germany ]
WGK 2 | [Storage Class]
3 - Flammable liquids | [Hazard Classifications]
Acute Tox. 3 Dermal
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral
Flam. Liq. 2
STOT SE 1 |
| Hazard Information | Back Directory | [Description]
Ursodeoxycholic acid-d4 (UDCA-d4) is intended for use as an internal standard for the quantification of UDCA (Item No. 15121) by GC- or LC-MS. UDCA is a secondary bile acid formed via epimerization of chenodeoxycholic acid (CDCA; ). UDCA is also a metabolite of lithocholic acid (LCA; ) in human liver microsomes. It inhibits taurocholic acid uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM. UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid (DCA; Item Nos. 20756 | 18231) or ethanol in primary rat hepatocytes. Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis. | [Uses]
Ursodeoxycholic Acid-d4 is a deuterated form of Ursodeoxcholic Acid (U850000), which is used as an anticholelithogenic. Ursodeoxcholic Acid is an epimer with Chenodiol with respect to the hydroxyl group at C7. Ursodeoxycholic Acid-d4 was used as an internal standard for rapid quantification of bile acids by liquid chromatography-tandem mass spectrometry. | [storage]
Store at -20°C | [References]
[1] PAUL A DAWSON Saul J K. Intestinal transport and metabolism of bile acids.[J]. Journal of Lipid Research, 2015, 56 6: 1085-1099. DOI: 10.1194/jlr.r054114
[2] ANAND K DEO S M B. 3-ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid.[J]. Drug Metabolism and Disposition, 2009, 37 9: 1938-1947. DOI: 10.1124/dmd.109.027763
[3] R B KIM. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 291 3: 1204-1209.
[4] C M RODRIGUES. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.[J]. Journal of Clinical Investigation, 1998, 101 12: 2790-2799. DOI: 10.1172/jci1325 |
|
|